Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003256
Status:
COMPLETED
Last Update Posted:
2013-02-11
First Post:
1999-11-01
Brief Title:
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate
II Assess the toxic effects of flavopiridol in this patient population
OUTLINE
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses After 2 courses of treatment patients not experiencing unacceptable toxic effects may receive a dose escalation Patients are followed every 3 months until death
I Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate
II Assess the toxic effects of flavopiridol in this patient population
OUTLINE
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses After 2 courses of treatment patients not experiencing unacceptable toxic effects may receive a dose escalation Patients are followed every 3 months until death
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-T97-0038 | None | None | None |
| WCCC-CO-9781 | None | None | None |